Europe and the Americas Animal Vaccine Market 2022-2028

Europe and the Americas Animal Vaccine Market 2022-2028

Vaccination has a significant role in protecting animal and public health by preventing them from infectious diseases, such as rabies, distemper, flu, and hepatitis, among others. The increasing trend for the pet as a companion increases the possibility of zoonotic diseases (disease passing from animals & insect to people), which acts as one of the major factors for the growth of the market across the regions. According to the Centers for Disease Control and Prevention (CDC), zoonotic diseases are very common in the US and Europe. It is estimated that over 6 out of 10 infectious diseases in humans are spread from animals in the US. Moreover, over 3 out of every 4 unknown or new infectious diseases in humans are spread from animals. CDC and other healthcare organizations are focused to prevent such a large spread of zoonotic diseases. This increases the demand for preventive vaccination, which in turn, fuels the demand for animal vaccines across the region.

On the basis of the type of vaccines, the market is segmented into porcine vaccines, poultry vaccines, livestock vaccines, aquaculture vaccines, companion animal vaccines, and other animal vaccines. Companion animal vaccines contribute the largest share of 31.8% in the market. The companion animal vaccine market is estimated to reach nearly $3.6 billion in 2028 from around $2.4 billion in 2021, growing at a CAGR of 7.2%, during the forecast period. The high trend for pet adoption along with the strict regulations for the vaccination of pets are major factors offering growth to the companion animal vaccine market. According to the American Pet Products Association, in the US, an estimated 90 million dogs and 94 million cats are owned accounting for 44% of households owning dogs, and 35% owing cat during 2017-2021. In 2021, the outbreak of the COVID-19 pandemic has largely impacted the production and consumption of meat and pork. Conversely, the companion animal vaccine segment is experiencing a marginal downfall in 2021 when compared to livestock and porcine vaccines. This is due to the large impact of the outbreak of COVID-19 pandemic on production of the meat. For instance, Tyson Foods, the largest meat producer of the US, decided to shut down two of its biggest pork plants in Indiana and Iowa. Therefore, the companion animal vaccine will contribute the major share in the animal vaccine market even during the outbreak, as the government organizations have asked vets to remain working even during the lockdown.

On the basis of technology, the market is segmented into a live attenuated vaccine, killed/inactivated vaccine, recombinant vaccines, and other vaccines. These are the most sustainable and cost-effective technique to control infectious animal diseases. The live attenuated vaccines held the largest share of 40.3% in the animal vaccine market in 2021. This is attributed to the ease of administration and long-term immunity offered by the live attenuated vaccine technologies. The value of the live attenuated vaccine market was around $3.0 billion in 2021, which is estimated to reach nearly $4.1 billion in 2028. The live attenuated vaccine market is growing at a CAGR 6.0% during the forecast period, owing to its high effectivity as they stimulate both humoral and cellular responses. Live attenuated vaccines offer significant benefits for animals over the inactivated vaccine. For instance, live attenuated vaccines can be administered via injection or natural route (oral or respiratory) whereas, killed/inactivated vaccine administered via injection only. Due to the various advantages of live attenuated vaccines compared to killed/inactivated vaccines, the market share of live attenuated vaccines is high.

The America & Europe animal vaccine market is also analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. Geographically, the market is divided into North America, Europe, and Latin America. North America is estimated to be the largest market for animal vaccines, followed by Europe. The North American animal vaccine market was valued at around $3.8 billion in 2021, which is estimated to reach nearly $5.6 billion in 2028. The high adoption rate of pets and their mandatory vaccination are the major factors for the growth of the North American market. The North American animal vaccine market is growing at a fastest CAGR of 7.3% owing to high meat consumption and the presence of a major market player in the region. Europe contributes a significant share in the animal vaccine market. The market value in the European region was nearly $2.8 billion in 2021, which is estimated to grow at a CAGR of 6.3% and hit nearly $3.9 billion in 2028. The increasing research on the animal vaccine in order to replace antibiotics and promote effective animal husbandry process can be considered as the major factor driving the market growth in Europe.

The companies contributing to the growth of the America & Europe animal vaccine market that includes Boehringer Ingelheim International GmbH, Ceva Animal Health LLC, Merck & Co., Inc., Bayer AG, Zoetis, Inc., and Virbac S.A. These market players are adopting various strategies to capitalize on market opportunities. Mergers and acquisitions, new product launch, geographical expansion, partnerships, and collaborations are some of the key strategies adopted by the market players.

In May 2021, Merck Animal Health, a division of Merck & Co., Inc. had signed a definitive agreement with Virbac, animal health product provider company to acquire the US rights to SENTINEL FLAVOR TABS and SENTINEL SPECTRUM Chews in the Companion Animal category. This will reinforce Merck Animal Health’s commitment to improving the business of the company in the US Companion Animal category.

In March 2021, Hipra S.A. has expanded its smart vaccination range to include the new vaccines: EVANT vaccine against avian coccidiosis in broilers which incorporates the adjuvant HIPRAMUNET, and GUMBOHATCH, the first immune complex vaccine from HIPRA for the prevention of Gumboro diseases.

In February 2021, Boehringer Ingelheim had received a grant from the EU to perform the marketing of Aservo EquiHaler. Aservo EquiHaler is a licensed inhalant therapy that is used to treat severe equine asthma. With this grant, the company intends to expand its market presence.

In October 2021, Bayer Animal Health GmbH, the subsidiary of Bayer AG had entered into a collaboration with VLPbio, an animal vaccine provider company. The agreement was made by both the companies to jointly develop and discover immunotherapeutics for animals based on VLPbio´s technology.